Using androgen receptor targeting to improve bladder cancer treatment with immune therapies
Targeting the Androgen Receptor to Sensitize Bladder Cancer to Immune Check Point Blockade.
['FUNDING_R21'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-11003717
This study is looking at whether a treatment that lowers male hormones can help make immune therapies work better for people with bladder cancer who haven't had much success with current options.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11003717 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting the androgen receptor can enhance the effectiveness of immune checkpoint blockade therapies in bladder cancer patients. Many patients with bladder cancer do not respond well to current immune therapies, and this study aims to explore how androgen deprivation therapy, commonly used in prostate cancer, can improve outcomes. By using preclinical mouse models and advanced techniques like single cell transcriptomics, the research will examine how these treatments can alter the immune environment in bladder tumors. The goal is to find new ways to make existing therapies more effective for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer, particularly those with androgen receptor-positive tumors.
Not a fit: Patients with bladder cancer who do not have androgen receptor-positive tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for bladder cancer patients who currently have limited responses to immune therapies.
How similar studies have performed: Previous research in prostate cancer has shown promising results using similar approaches, suggesting potential for success in bladder cancer as well.
Where this research is happening
NEW YORK, UNITED STATES
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MULHOLLAND, DAVID — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Study coordinator: MULHOLLAND, DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer